If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now

With so much hype around coronavirus vaccine stocks, it was easy to miss Personalis (NASDAQ: PSNL), which became a 10-bagger after the market crash last year. Personalis is a biotech that competes with Guardant Health (NASDAQ: GH) and Adaptive Biotechnologies (NASDAQ: ADPT) in the cancer genomics space. Other major competitors include NanoString Technologies (NASDAQ: NSTG) and Foundation Medicine, a subsidiary of Roche Holdings (OTC: RHHBY).